



The effect of COVID-19 on hepatic enzymes AST/ALT: A review

Saba Ameli ¹, Behnaz Mahmoodieh ¹, Negin Dehghanipour ², Ssara Babran ¹ and Sanaz Saleh ^{1,*}

¹ Department of Medical Sciences, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

² Department of pharmaceutical chemistry (pharmaceutical chemistry), Tehran Branch, Islamic Azad University, Tehran, Iran.

Open Access Research Journal of Biology and Pharmacy, 2022, 05(02), 015–019

Publication history: Received on 10 June 2022; revised on 16 July 2022; accepted on 18 July 2022

Article DOI: <https://doi.org/10.53022/oarjbp.2022.5.2.0053>

Abstract

The latest coronavirus pandemic, originated by the human coronavirus or SARS-CoV-2, has developed into a crucial global health affair over the past 2 years. These viruses are acclaimed to trigger a range of respiratory and enteric disorders in a diverse group of organisms and humans. Coronavirus have also been reported to cause respiratory failure, the complication of sepsis, and one or numerous organ failure. Several studies revealed that coronavirus-positive individuals had a liver injury. In those individuals, the increased levels of hepatic enzymes mainly AST and ALT and signs of inflammation were analyzed in complex clinical cases According to recent clinical data, abnormal levels of AST/ALT are more often noticed in coronavirus positive patients, but the fundamental pathogenesis is still not known entirely. We evaluated the current literature on COVID-19 and its effect on AST/ALT levels in coronavirus-positive patients.

Keywords: Covid-19; Hepatic enzymes; AST; ALT

1. Introduction

Coronavirus is associated with a group of viruses that are acclaimed to trigger a range of respiratory and enteric disorders in a diverse group of organisms and humans [1]. Human coronaviruses are liable to attack the upper airway, resulting in varying degrees of complications, including upper respiratory infections in severe cases, and pneumococcal disease. Besides coronavirus vaccination, several effective mouthrinses can be used to decrease the spread of coronavirus infection. Until now, 7 novel coronaviruses entailing 3 pandemic-causing viruses of SARS-CoV-2, MERS-CoV and the recently evolved coronavirus or SARS-CoV-2 [2-5]. These pandemic-causing viruses share indistinguishable nucleotide sequences [6]. In December 2019, a string of pneumococcal cases of unspecified origin commence expanding in central China. At present recognized as SARS-CoV-2, more than 300,000 individuals around the world had been infected by this virus [7]. The World Health Organization (WHO) has designated coronavirus or COVID-19 a pandemic that has resulted in loads of demises and hospitalizations around the world. Even-though mild manifestations including headache have been reported in most coronavirus cases, more severe investigations have resulted in respiratory failure, the complication of sepsis, and one or numerous organ failures [8, 9]. While this fatal disease proceeds to disseminate, additional clinical and endemic features should be illuminated to increase our knowledge regarding the true scope of the virus, to improve diagnostic and management potentials and its effect on the rate of morbidity and mortality.

Recently, it has been perceived that coronavirus can influence the activity of other organs, while numerous pieces of evidence have demonstrated that nearly all coronavirus patients showed a different extent of hepatic disease [10]. The latest study established that coronavirus can gird to ACE-related carboxypeptidase or (ACE2) on epithelial cells also labelled as cholangiocytes, inducing cholangiocyte disorder and causing inflammation of the whole body resulting in liver injury [11]. From March 10, 2020, till now, different extensive clinical studies have demonstrated the clinical

* Corresponding author: Sanaz Saleh

Department of Medical Sciences, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

features of individuals with coronavirus disease, along with some understanding of other aspects, which may cause coronavirus-related liver damage [12-18]. Increased concentrations of alanine transaminase (ALT) and aspartate transaminase (AST) were expressed in these studies were expressed, ranging between 14%-53% [12,13,15,18]. In addition, temperate accumulation of hepatic fat and slight lobular, as well as portal activity, was seen in a study of liver specimen obtained with the aid of biopsy via individuals who deceased from coronavirus disease, demonstrating that coronavirus possibly have resulted in liver damage [19]. Nonetheless, compact data persists that has carefully examined additional enzymes and manifestations of hepatic failure among individuals with coronavirus. Therefore, the main objective of this

2. Prevalence and pathophysiology of liver abnormalities after coronavirus disease

Liver damage may consist of different types and have numerous factors in nature, hence comprehensive diagnostic study and constant monitoring are needed to assess their clinical appropriateness. Significantly, it is required to ascertain if liver damage is associated with a chronic liver condition, therapy utilized for management, the explicit reaction of coronavirus, or dysregulated non-specific immunity. A study carried out in the US revealed that 25% of coronavirus positive individuals had a liver injury. In those individuals, the increased levels of hepatic enzymes mainly AST and ALT and signs of inflammation were analyzed in complex clinical cases. The average age of hepatic abnormalities after coronavirus disease infection was 50 years, accompanied by 56% male dominance. Preexisting hepatic conditions were present in 2% of cases only. No correlation was observed between the existence of liver function loss and digestive manifestations, but elevated levels of AST and ALT led to elevated rates of patients admitted to intensive care units.

Coronavirus disease resulting in hepatic injury and digestive disorders induces presentation of several extrapulmonary manifestations including vomiting, discomfort, loose stools and anorexia. The explicit invasion of coronavirus is the major reason behind acute liver damage after coronavirus infection resulting in the demolition of hepatic cells, vascular endothelins or thrombosis, cytokine storm, low oxygen levels and drug-induced hepatotoxicity induced by the utilization of drugs such as acetaminophen and remdesivir [20].

3. Effect of coronavirus on AST and ALT

Research has supported the fact that coronavirus-positive individuals have liver damage and atypical hepatic function tests. Various studies have observed the high prevalence of AST and ALT M elevation and liver damage. The symptoms of coronavirus infection vary from slight to extremely sick and lethal cases. Individuals with serious coronavirus infections may have a greater probability of liver damage. Till now, a research gap is present related to the degree of liver damage and enhanced transaminase concentrations stratified by coronavirus infection severity [21].

Numerous case studies have revealed atypical hepatic function tests in individuals with coronavirus disease [12,22,23]. In another study, several groups were formed deployed on the acuteness of COVID-19 infection revealed that severe coronaviruses positive individuals had a greater extent of ALT and AST in comparison to individuals with slight infection [15].

The speculation that could demonstrate the outcomes of coronavirus diseases in the hepatic system is associated with the existence of angiotensin-converting enzyme 2 receptors. Coronavirus can easily target the liver due to the expression of angiotensin-converting enzyme 2 receptors on cholangiocytes. During the inspection of the COVID-19 patient's liver, hepatic endothelium [25,26] was observed, and sinusoidal capillaries revealed fibrin microthrombi [27]. During the examination of 48 hepatic biopsies, hepatic sinusoids showed portal hypertension, luminal blood clots, portal fibrotic scarring and sinusoidal microthrombi.

Keep in view of the literature mentioned above, elevated levels of hepatic enzymes are noticed in critically ill coronavirus patients. Cai et al. in their study concluded that alterations in LFTs can be seen to elevate 7 times due to the delivery of lopinavir-ritonavir [28]. Comparably, a study conducted by 199 critically-ill COVID-19 positive patients revealed that elevations in ALT and AST were frequently noticed in the group receiving lopinavir-ritonavir in comparison to the group which did not acquire it. Immediate recovery of coronavirus patients has been proclaimed due to Remdesivir [29]. A significant elevation in ALT/AST extents was observed in a study evaluating Remdesivir therapy for 5-10 days in almost 4-6% of subjects while life-threatening in 2-3% of subjects, resulting in the abrogation of therapy [30]. Acetaminophen, a well-known medication utilized for the management of COVID-19 manifestations, is considered to cause alterations in ASALT despite usual doses. While earlier data hardly exist related to hydroxychloroquine and its major consequences on LFTs [31].

This study presupposes the objective that coronavirus-positive individuals should be checked for abnormal LFTs intermittently for improved management of this infection. Nonetheless, more studies with a greater sample size are needed to the confirmation of outcomes obtained from this study; whoever, with rising of the new variants it is important to more studies continue to observe the side effects of this disease [32].

4. Conclusion

Hepatic enzymes are often unbalanced in individuals admitted with coronavirus infection. Hepatic enzymes must be frequently observed throughout the treatment course of coronavirus disease, as several drugs utilized in the management of coronavirus infection may promote the deterioration of hepatic enzymes and may lead to extended damage.

Compliance with ethical standards

Disclosure of conflict of interest

There is no conflict of interest.

References

- [1] Dong Y, Liang X, Yu X. *Zhonghua wei zhong bing ji jiu yi xue*. 2019; 31(5): 571–576.
- [2] Ghasemi S, Dashti M. Fight against COVID-19 with mRNA vaccines and interaction with Dermal fillers. *Clin Exp Vaccine Res*. 2021 May;10(2):151-153. <https://doi.org/10.7774/cevr.2021.10.2.151>
- [3] Niu P, Shen J, Zhu N, Lu R, Tan W. Two-tube multiplex real-time reverse transcription PCR to detect six human coronaviruses. *Virologica Sinica*. 2016; 31(1): 85–88.
- [4] Ghasemi S, Dashti M. Using mouthwashes by a healthcare practitioner in order to decrease the chance of transmission of covid-19. *J Dent Oral Disord*. 2021;7(3) <https://doi.org/10.26420/jdentoraldisord.2021.1165>
- [5] Shohreh Ghasemi, Zohreh Mortezaia, Maryam Mohammad Alizadeh Chafjiri, & Mahmood Dashti. (2022). Increase of fake Covid-19 vaccination card and test certification. *International Journal of Biological and Pharmaceutical Sciences Archive*, 3(2), 133–135. <https://doi.org/10.53771/ijbpsa.2022.3.2.0064>
- [6] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet (London, England)*. 2020; 395(10224): 565–574.
- [7] Jia Z, Yan L, Ren Z, Wu L, Wang J, Guo J, Zheng L, Ming Z, Zhang L, Lou Z, Rao Z. Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis. *Nucleic acids research*. 2019; 47(12): 6538–6550.
- [8] Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020; 323(13): 1239–1242.
- [9] Baban B, Stevens MR, Ghasemi S, Boojar FMA, Dashti M. New manifestation of Covid-19 in oral region, a potential faster diagnosis approach, a mini review. *J Dent Oral Epidemiol*. 2021; 1(1). <https://doi.org/10.54289/JDOE2100103>
- [10] Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, Choi KW, Tso YK, Lau T, Lai ST, Lai CL. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatology (Baltimore, Md.)*. 2004; 39(2): 302–310.
- [11] Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *bioRxiv*. 2020.
- [12] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*. 2020; 395(10223): 507–513.

- [13] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020; 395(10223): 497–506.
- [14] Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, Chen G, Zhang Y, Li D, Li J, Lian H, Niu S, Zhang L, Zhang J. Characteristics of COVID-19 infection in Beijing. *The Journal of infection*. 2020; 80(4): 401–406.
- [15] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui D, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020; 382(18): 1708–1720.
- [16] Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *The Journal of infection*. 2020; 80(4): 388–393.
- [17] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020; 75(7): 1730–1741.
- [18] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020; 323(11): 1061–1069.
- [19] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet. Respiratory medicine*. 2020; 8(4): 420–422.
- [20] Su YJ, Chang CW, Chen MJ, Lai YC. Impact of COVID-19 on liver. *World journal of clinical cases*. 2021; 9(27): 7998–8007.
- [21] Li G, Yang Y, Gao D, Xu Y, Gu J, Liu P. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. *International journal of medical sciences*. 2021; 18(5): 1285–1296.
- [22] Weber S, Mayerle J, Irlbeck M, Gerbes AL. Severe liver failure during SARS-CoV-2 infection. *Gut*. 2020; 69(7): 1365–1367.
- [23] Wander P, Epstein M, Bernstein D. COVID-19 Presenting as Acute Hepatitis. *The American journal of gastroenterology*. 2020; 115(6): 941–942.
- [24] Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver international: official journal of the International Association for the Study of the Liver*. 2020; 40(9): 2095–2103.
- [25] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. *Lancet (London, England)*. 2020; 395(10234): 1417–1418.
- [26] Sanaz Saleh, Ardalan Panahi Sharif, Ali Panahi Sharif, Emad Alamouti-Fard, & Seyedeh Saba Ameli. (2022). COVID-19 and organ transplant recipients, risk factors and considerations: A mini-review. In *International Journal of Biological and Pharmaceutical Sciences Archive* (Vol. 3, Issue 2, pp. 136–140). Scientific Research Archives. <https://doi.org/10.53771/ijbpsa.2022.3.2.0066>
- [27] Duarte-Neto AN, Monteiro R, da Silva L, Malheiros D, de Oliveira EP, Theodoro-Filho J, Pinho J, Gomes-Gouvêa MS, Salles A, de Oliveira I, Mauad T, Saldiva P, Dolhnikoff M. Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. *Histopathology*. 2020; 77(2): 186–197.
- [28] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *Journal of hepatology*. 2020; 73(3): 566–574.
- [29] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G. ACTT-1 Study Group Members Remdesivir for the Treatment of Covid-19 – Final Report. *The New England journal of medicine*. 2020; 383(19): 1813–1826.
- [30] Goldman JD, Lye D, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, Sen Gupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggari A, Brainard DM, Towner WJ... GS-US-540-5773

Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *The New England journal of medicine*. 2020; 383(19): 1827–1837.

- [31] Naeem A, Khamuani MK, Kumar P, Pooja F, Raj D, Lal K, Shahid W, Mahar W, Rizwan A, Fatima A. Impact of Coronavirus Diseases on Liver Enzymes. *Cureus*. 2021; 13(9): e17650.
- [32] Shohreh Ghasemi, Zohreh Mortezaia, Sanaz Gholami Toghchi, & Mahmood Dashti. (2022). New unknown Sars-Cov-2 virus variants and hidden pandemics within them in developing countries. *International Journal of Biological and Pharmaceutical Sciences Archive*, 3(2), 127–132. <https://doi.org/10.53771/ijbpsa.2022.3.2.0063>